Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada

GlobeNewswire June 3, 2021

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.

Newsfile May 21, 2021

Resverlogix Announces US$6 Million Debenture Financing

GlobeNewswire May 5, 2021

Resverlogix’s (TSX:RVX) apabetalone breaks new ground in chronic kidney disease treatment

Trevor Abes  April 27, 2021

Resverlogix's Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

GlobeNewswire April 27, 2021

Zenith Epigenetics Announces Clinical Collaboration with Astellas

GlobeNewswire April 22, 2021

Apabetalone's Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines

GlobeNewswire April 20, 2021

Health Canada authorizes Resverlogix (TSX:RVX) to begin clinical studies of Apabetalone for COVID-19

John Ballem  April 12, 2021

Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19

GlobeNewswire April 12, 2021

Apabetalone’s beneficial effects on COVID-19 patients published in a prestigious scientific journal

Trevor Abes  March 17, 2021

Apabetalone's Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell

GlobeNewswire March 17, 2021

Resverlogix (TSX:RVX) apabetalone treatment prevents COVID-19 in human lung cells

Trevor Abes  March 15, 2021

Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells

GlobeNewswire March 15, 2021

Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck's Immune Check Point Inhibitor KEYTRUDA

GlobeNewswire March 15, 2021

Resverlogix Announces Change in Fiscal Year-End to December 31

GlobeNewswire March 12, 2021

New Published Evidence of Apabetalone's Beneficial Effects on COVID-19

GlobeNewswire March 3, 2021

Resverlogix Reschedules Update Webcast and Conference Call

GlobeNewswire January 27, 2021

Resverlogix Announces Update Webcast and Conference Call

GlobeNewswire January 18, 2021

Publication finds Resverlogix (TSX:RVX) publishes positive Apabetalone results

Isabella Zavarise January 14, 2021

Apabetalone's Positive Effect on Hospitalized Patients Involving Heart Failure

GlobeNewswire January 12, 2021